[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benzodiazepine-dependence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benzodiazepine-dependence":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,81,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100498084","effectiveness-of-a-joint-general-practitioner-pharmacist-intervention-on-benzodiazepine-deprescribing-in-the-elderly-100498084",false,"NCT05765656","Effectiveness of a Joint General Practitioner-Pharmacist Intervention on Benzodiazepine Deprescribing in the Elderly","Evaluation of the Effectiveness of a Joint General Practitioner-Pharmacist Intervention on the Implementation of Benzodiazepine Deprescribing in the Elderly (BESTOPH-MG Trial): Protocol for a Cluster-randomized Controlled Trial","BESTOPH-MG","Inclusion Criteria:\n\n* outpatients aged 65 and over\n* followed by the general practitioner and the pharmacist of the GP-PO pair\n* having a prescription for an anxiolytic or hypnotic BZDR prescribed at least 4 times in the past year\n* the last prescription being less than 3 months old\n* having been dispensed monthly during the last 3 months\n* affiliated to a social security scheme\n* and having given consent to participate in the research.\n\nExclusion Criteria:\n\n* patients living in an institution\n* participating in a clinical trial\n* with epilepsy\n* active depression\n* uncontrolled mental disorders\n* unable to participate in an interview or answer a questionnaire (demented, non-French speaking, illiterate, deaf, ...)\n* under guardianship\n* with a dystonic syndrome\n* and patients who are not sufficiently autonomous to carry out the steps inherent in the study","ALL","65 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","Benzodiazepines or related drug (BZDR) are consumed for hypnotic or anxiolytic purposes in most cases. The consequences of BZDR are multiple with an increased risk of daytime sedation, balance disorders leading to falls and fractures, cognitive disorders, road accidents and dementia. Given their comorbidities, physiological changes, and multiple medications, the elderly are more at risk of suffering from BZDR adverse events.\n\nInterprofessional collaboration has shown efficacy in improving prescribing appropriateness and may affect patients outcomes positively. Morever, motivational interviews (MI) may reduce the extent of substance abuse compared to no intervention.",[27,28,29,30,31,32],"Primary Care","Health Plan Implementation","Benzodiazepine Dependence","Elderly","Anxiety","Deprescribing",[34,35,36,37,38,39],"Primary care","collaborative practice","health plan implementation","deprescribing","benzodiazepine","elderly","RECRUITING","2026-06-19",{"date":43,"type":44},"2026-06-24","ACTUAL",{"date":46,"type":44},"2023-10-16",{"date":48,"type":21},"2027-02-16",{"name":50,"class":51},"Nantes University Hospital","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":18,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100511139","phase-2-baclofen-for-improving-benzodiazepine-titration-in-benzodiazepine-dependence-100511139","NCT05935553","Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence","BABET","Inclusion Criteria:\n\n* Patients aged ≥ 18 years to ≤ 65 years\n* For women of childbearing potential :\n\n  * negative pregnancy test at inclusion\n  * and use of effective contraception which will be continued throughout the trial period\n  * and agrees to carry out pregnancy tests throughout the trial period.\n* BUD of any severity defined according to Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 criteria\n* Average daily benzodiazepine dosage between 30 mg and 200 mg-diazepam (according to Ashton equivalence table) over the 28 days prior to inclusion. Benzodiazepine equivalents (zolpidem, zopiclone and eszopiclone) will be counted as part of the total equivalent daily dose of diazepam and will also be included in the tapering procedure.\n* Continued use of benzodiazepines for more than 12 weeks\n* At least one history of BUD treatment failure. A treatment failure is defined as a failure to withdraw from the full dose (i.e., discontinuation of benzodiazepine and related prescriptions) according to a previously established tapering schedule, by a general practitioner or specialist\n* Patient affiliated to a social security system.\n* Patients with or without guardianship\n* Patient capable of giving free, informed and written consent.\n\nExclusion Criteria:\n\n* Cirrhosis of the liver\n* Patients with significant medical conditions such as cancer, HIV, epilepsy, chronic respiratory failure, renal failure, etc.\n* Non-compatible health conditions (at the discretion of the investigator)\n* The following psychiatric conditions as defined by DSM-5 criteria: schizophrenic disorder, persistent delusional disorder, schizophreniform disorder, schizoaffective disorder, bipolar disorder, autism spectrum disorder identified using the Mini International Neuropsychiatric Interview version 7.0.2 (MINI 7.0.2)\n* Suicidal state identified using MINI 7.0.2\n* Dependence on substances or drugs other than benzodiazepines and nicotine (dependence will be identified through the use of MINI 7.0.2)\n* History of baclofen use for all indications\n* Unauthorized combination therapies will be: pregabalin, topiramate, ketamine, sodium oxybate, gabapentin, valproic acid, sodium valproate, melatonin, buspirone, hydroxyzine, propranolol, bisoprolol, etifoxin, carbamazepine, clonidine, paroxetine, all neuroleptic\u002Fantipsychotic class therapies, and tricyclic antidepressants\n* Pregnant or nursing women\n* Hypersensitivity to baclofen or microcrystalline cellulose.\n* Participants under guardianship\n* Patients who need to drive and\u002For use machines during the 1-week dose escalation phase","18 Years",{"count":62,"type":21},93,[64,65],"PHASE2","PHASE3","Benzodiazepines and related molecules are among the most prescribed psychotropic treatments in France and Europe. 13.4% of the French population had at least one reimbursement of benzodiazepines in 2015, which places France second in Europe.\n\nHowever, the chronic use of benzodiazepines is a source of numerous complications, particularly addictive. To date, there is no authorized pharmacological treatment for benzodiazepine withdrawal.\n\nBaclofen is a gamma-aminobutyric acid (GABA)-B agonist, a pharmacological receptor that regulates GABA-A, the target of benzodiazepines. The pharmacological mechanisms of baclofen are therefore related to those of benzodiazepines. Empirical use outside of the MA has shown that baclofen can facilitate the reduction of benzodiazepines in cases of severe addiction, but this pharmaceutical interest remains to be demonstrated in a comparative study.\n\nThe main objective of the project is to evaluate the efficacy of baclofen, compared to placebo, in reducing benzodiazepine doses in patients with benzodiazepine use disorder (BUD).",[29],[29,69,70],"baclofen","efficacy","2026-05-07",{"date":73,"type":44},"2026-05-11",{"date":75,"type":44},"2026-01-15",{"date":77,"type":21},"2028-10-30",{"name":79,"class":51},"Hospices Civils de Lyon",2,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":60,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":52},"100535362","benzodiazepine-impact-on-cognitive-function-fnirs-and-petmri-study-100535362","NCT06250842","Benzodiazepine Impact on Cognitive Function: fNIRs and PET\u002FMRI Study","Assessing the Cognitive Effects of Chronic Benzodiazepine Use in Patients: A Comprehensive Study Using fNIRs and PET\u002FMRI Technologies","Inclusion Criteria:\n\n1. Continuous use of benzodiazepines for ≥3 months, matched with participants who have not taken benzodiazepines.\n2. Education time ≥6 years.\n3. Abstained from alcohol, coffee, and other psychoactive substances in the 24 hours before the examination.\n\nExclusion Criteria：\n\n1. Brain damage due to various reasons (such as head trauma, dementia, epilepsy, brain tumors, etc.).\n2. Severe systemic diseases (such as malignant tumors, etc.).\n3. Acute cerebrovascular disease in the past 3 months. History of substance abuse other than benzodiazepines (such as alcohol, opioids, etc.).\n4. Inability to cooperate with fNIRS, PET\u002FMRI examinations, and scale assessments.",true,"80 Years",{"count":91,"type":21},100,"OBSERVATIONAL","This study explores the impact of long-term benzodiazepine (BZDs) use on cognitive function and associated neuroimaging markers. While BZDs are established treatments for conditions like anxiety and insomnia, recent warnings highlight risks, including neurocognitive effects. Neuroimaging studies indicate potential neuroprotective effects of BZDs. Functional near-infrared spectroscopy (fNIRS) measures cerebral cortex function during cognitive tasks. Combining fNIRS with mood and cognitive scales, this study assesses cortical activation. 2-deoxy-2-fluoro-D-glucose-positron emission tomography (FDG-PET) evaluates brain metabolism. DPA-714 PET assesses neuroinflammation. The primary objective is to compare brain functional activation, metabolism, and neuroinflammatory levels between long-term BZD users and non-users. This comprehensive approach aims to provide insights into BZD effects on cognition and associated brain markers.",[95,96,29],"Benzodiazepine Adverse Reaction","Depression, Anxiety",[98,99,100,101,102],"Benzodiazepines","Long Term Adverse Effects","Cognitive Neuroscience","Neuroendocrinology","immunomodulatory potential","2025-04-09",{"date":105,"type":44},"2025-04-11",{"date":107,"type":44},"2024-02-11",{"date":109,"type":21},"2027-06-30",{"name":111,"class":51},"The First Affiliated Hospital of Dalian Medical University",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":18,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":52},"100574302","phase-2-effects-of-intranasal-oxytocin-in-the-treatment-of-benzodiazepine-withdrawal-a-pilot-rct-100574302","NCT06757517","Effects of Intranasal Oxytocin in the Treatment of Benzodiazepine Withdrawal: A Pilot RCT","Effects of Intranasal Oxytocin in the Treatment of Benzodiazepine Withdrawal: A Pilot Randomized Parallell Group Placebo-Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18 - 65 years, taking benzodiazepines at a daily dose of 20-80 mg diazepam-equivalent, and requiring inpatient benzodiazepine withdrawal. Included patients must consent to participate in the study.\n\nExclusion Criteria:\n\n* Female patients will be excluded if they are pregnant or are planning to become so, or if they are breast-feeding. Individuals incapable of completing questionnaires or giving informed consent will be excluded. Patients with concurrent acute medical or psychiatric illness requiring acute care hospitalization, misuse or dependency of alcohol or pregabalin\u002Fgabapentin will be excluded.",{"count":120,"type":21},60,[64],"The goal of this clinical trial is to learn if oxytocin administered as a nasal spray will reduce withdrawal symptoms in adults during benzodiazepine tapering for 21 days. It will also learn about the safety of oxytocin. The main question it aims to answer are:\n\nDoes oxytocin reduce benzodiazepine withdrawal symptoms and make it easier to succeed tapering? Does oxytocin help reduce sleep difficulties and anxiety or restlessness during benzodiazepine tapering? Does oxytocin help reduce benzodiazepine craving?\n\nWe will compare oxytocin nasal spray to a placebo nasal spray containing regular saline to see if oxytocin works accordingly.\n\nParticipants will:\n\nTake oxytocin or a placebo nasalspray, thrice daily for 21 days during inpatient benzodiazepine tapering.\n\nFill out an online questionnaire every day and keep a record of their symptoms.",[29],[125,126,127,128,129],"intranasal oxytocin","oxytocin","benzodiazepines","benzodiazepine dependence","benzodiazepine withdrawal","2025-01-02",{"date":132,"type":44},"2025-01-03",{"date":134,"type":44},"2022-03-01",{"date":136,"type":21},"2025-12-31",{"name":138,"class":51},"St. Olavs Hospital"]